20076-54-4

Basic information

• Product Name: 5,6-DICHLOROBENZIMIDAZOLE
• Synonyms: BUTTPARK 121\15-71;5,6-DICHLORO-1H-1,3-BENZIMIDAZOLE;5,6-DICHLORO-1H-BENZIMIDAZOLE;5,6-DICHLORO-1H-BENZO[D]IMIDAZOLE;5,6-DICHLOROBENZIMIDAZOLE;1H-BENZIMIDAZOLE, 5,6-DICHLORO-;5,6-Dichlorobenzoimidazole;2-Methylthio-5,6-dichlorobenzimidazol
• CAS NO: 20076-54-4
• Molecular Formula: C₈H₆Cl₂N₂S
• Molecular Weight: 187.03
• Mol File: 20076-54-4.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5,6-DICHLOROBENZIMIDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6-DICHLOROBENZIMIDAZOLE(20076-54-4)
• EPA Substance Registry System: 5,6-DICHLOROBENZIMIDAZOLE(20076-54-4)

Safety Data

• Hazardous Substances Data: 20076-54-4(Hazardous Substances Data)

Usage

General Description

5,6-Dichlorobenzimidazole is a chemical compound with the molecular formula C7H4Cl2N2. It is a white to light yellow crystalline powder that is insoluble in water but soluble in organic solvents. 5,6-DICHLOROBENZIMIDAZOLE is primarily used as an intermediate in the production of pharmaceuticals, particularly antifungal drugs. It has also been studied for its potential use as a corrosion inhibitor in the oil and gas industry due to its ability to inhibit the growth of sulfate reducing bacteria. Additionally, 5,6-Dichlorobenzimidazole is used in the synthesis of fluorescent dyes and pigments. Given its various applications, this chemical is important in several industries and is subject to regulatory controls to ensure its safe handling and use.

Upstream product

• 5348-42-5 4,5-Dichloro-1,2-phenylenediamine 
• 19462-98-7 5,6-dichloro-1H-benzimidazole-2-thiol 
• 74-88-4 methyl iodide 
• 19462-98-7 5,6-dichloro-2,3-dihydro-1H-1,3-benzodiazole-2-thione 

Relevant articles and documents

Design, synthesis, and antitumor activity of PLGA nanoparticles incorporating a discovered benzimidazole derivative as EZH2 inhibitor

Purpose: Targeting enhancer of zeste homolog 2 (EZH2) can represent a hopeful strategy for oncotherapy. Also, the use of PLGA-based nanoparticles as a novel and rate-controlling carrier system was of our concern. Methods: Benzimidazole derivatives were synthesized, and their structures were clarified. In vitro antitumor activity was evaluated. Then, a modeling study was performed to investigate the ability of the most active compounds to recognize EZH2 active sites. Compound 30 (Drug) was selected to conduct pre-formulation studies and then it was incorporated into polymeric PLGA nanoparticles (NPs). NPs were then fully characterized to select an optimized formula (NP4) that subjected to further evaluation regarding antitumor activity and protein expression levels of EZH2 and EpCAM. Results: The results showed the antitumor activity of some synthesized derivatives. Docking outcomes demonstrated that Compound 30 was able to identify EZH2 active sites. NP4 exhibited promising findings and proved to keep the antitumor activity of Compound 30. HEPG-2 was the most sensitive for both Drug and NP4. Protein analysis indicated that Drug and NP4 had targeted EZH2 and the downstream signaling pathway leading to the decline of EpCAM expression. Conclusions: Targeting EZH2 by Compound 30 has potential use in the treatment of cancer especially hepatocellular carcinoma.

Synthesis and biological evaluation of benzo[d]imidazole derivatives as potential anti-cancer agents

We herein report the synthesis, biological activity and structure-activity relationship of derivatives of 5,6-dichloro-1-β-d- ribofuranosylbenzimidazole and benzo[d]imidazole. A lead compound 6o demonstrates potent anti-proliferative activity and the ability to induce cancer cell apoptosis.

2H-Benzimidazoles (Isobenzimidazoles). Part 7. A New Route to Triclabendazole and Congeneric Benzimidazoles

A new synthesis of the selective anthelmintic agent triclabendazole 7 from the readily available 5,6-dichloro-2H-benzimidazole-2-spirocyclohexane 2 by simple steps is described.Analogous benzimidazoles difficult to prepare by conventional methods are similarly obtained.Triclabendazole can exist as a low-melting metastable solid (m.p. 85-90 deg C) convertible by heating or recrystallisation from ethanol into its stable form (m.p. 176-178 deg C).